Tuberculosis and COVID-19: Medical and Social Aspects
https://doi.org/10.21292/2075-1230-2022-100-3-13-17
Abstract
The review considers data from 28 publications devoted to the specific impact of COVID-19 on the course of tuberculosis. It describes diagnosis and clinical manifestations in case of co-infection of these two diseases. Also, it discusses the social impact of lockdowns and restrictive measures taken during the COVID-19 pandemic on the treatment of tuberculosis. The article discusses the impact of BCG vaccination on the immune response to the coronavirus.
About the Authors
E. V. Savintseva
Izhevsk State Medical Academy
Russian Federation
Russian Federation
Elena V. Savintseva, Assistant of Department
0/1, Slavyanskoye Rd, Razyan, 426039
P. V. Isaeva
Izhevsk State Medical Academy
Russian Federation
Russian Federation
Polina V. Isaeva, Student of the VIth Year of Training, General Medicine Department
0/1, Slavyanskoye Rd, Razyan, 426039
G. F. Nizamova
Izhevsk State Medical Academy
Russian Federation
Russian Federation
Guzaliya F. Nizamova, Student of the VIth Year of Training, General Medicine Department
0/1, Slavyanskoye Rd, Razyan, 426039
References
1. WHO. Information Bulletin. March 2021. Sotsialnye Aspekty Zdorovya Naseleniya, 2021, no. 2 (67), pp. 19. (In Russ.)
2. Ekaterincheva O.L., Malkova А.M., Karev V.E., Kudryavtsev I.V., Zinchenko Yu.S., Potepun T.B., Kudlay D.А., Starshinova А.А. Specific parameters of tuberculosis diagnostics in case of concurrent COVID-19. Journal Infektologii, 2021, vol. 13, no. 1, pp. 117-123. (In Russ.)
3. Shvarts Ya.Sh., Stavitskaya N.V., Kudlay D.А. BCG vaccination as protection from COVID-19: epidemiological and molecular biological aspects. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 5, pp. 6-14. (In Russ.)
4. Ahmed S.M., Nasr M.A., Elshenawy S.E., Hussein A.E., El-Betar A.H., Mohamed R.H., El-Badri N. BCG vaccination and the risk of COVID 19: A possible correlation. Virology, 2022, vol. 565, pp. 73-81. https://doi.org/10.1016/j.virol.2021.10.003.
5. Amimo F., Lambert B., Magit A. What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? Trop. Med. Health, 2020, no. 48, pp. 32. https://doi.org/10.1186/s41182-020-00219-6.
6. Aspatwar A., Gong W., Wang S., Wu X., Parkkila S. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic. Intern. Rev. Immunol., 2022, vol. 41, no. 2, pp. 283-296. https://doi.org/10.1080/08830185.2021.1922685.
7. Bagheri N., Montazeri H. On BCG Vaccine Protection from COVID-19: A Review. SN Compr. Clin. Med., 2021, no. 3, pp. 1-11. https://doi.org/10.1007/s42399-021-00835-1.
8. Chen Y., Wang Y., Fleming J., Yu Y., Gu Y., Liu C., Fan L., Wang X., Cheng M., Bi L., Liu Y. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv, 2020. https://doi.org/10.1101/2020.03.
9. Chopra K.K., Arora V.K., Singh S. COVID 19 and tuberculosis. Indian J. Tuberc., 2020, vol. 67, no. 2, pp. 149-151. https://doi.org/10.1016/j.ijtb.2020.06.001. 2020.
10. Crisan-Dabija R., Grigorescu C., Pavel C.A., Artene B., Popa I.V., Cernomaz A., Burlacu A. Tuberculosis and COVID-19: Lessons from the past viral outbreaks and possible future outcomes. Can. Respir. J., 2020, vol. 2020, pp. 1401053. https://doi.org/10.1155/2020/1401053.
11. Davies M. HIV and risk of COVID-19 death: a population cohort study from the. Western Cape Province, South Africa. The preprint server for health sciences. 2020, no. 3. https://doi.org/10.1101/2020.07.02.20145185.
12. Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G., Yuan Z., Feng Z., Zhang Y., Wu Y., Chen Y. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front. Immunol., 2020, vol. 11, pp. 827. https://doi.org/10.3389/fimmu.2020.00827.
13. Etna M.P., Giacomini E., Severa M., Coccia E.M. Pro- and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin. Immunol., 2014, vol. 26, no. 6, pp. 543-551. https://doi.org/10.1016/j.smim.2014.09.011.
14. Gao Y., Liu M., Chen Y., Shi S., Geng J., Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. J. Med. Virol., 2021, vol. 93, no. 1, pp. 194-196. https://doi.org/10.1002/jmv.26311.
15. Iyengar K.P., Jain V.K. Tuberculosis and COVID-19 in India- double trouble! Indian J. Tuberc., 2020, no. 67 (4S), pp. 175-176. https://doi.org/10.1016/j.ijtb.2020.07.014.
16. Koupaei M., Naimi A., Moafi N., Mohammadi P., Tabatabaei F.S., Ghazizadeh S., Heidary M., Khoshnood S. Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients: A systematic review. Front. Med. (Lausanne), 2021, vol. 8, pp. 740593. https://doi.org/10.3389/fmed.2021.740593.
17. Mack U., Migliori G.B., Sester M., Rieder H.L., Ehlers S., Goletti D., Bossink A., Magdorf K., Hölscher C., Kampmann B., Arend S.M., Detjen A., Both G., Zellweger J.P., Milburn H., Diel R., Ravn P., Cobelens F., Cardona P.J., Kan B. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J., 2009, vol. 33, no. 5, pp. 956-973. https://doi.org/10.1183/09031936.00120908.
18. Marwah V., Peter D.K., Ajai Kumar T., Bhati G., Kumar A. Multidrug-resistant tuberculosis in COVID-19: Double trouble. Med. J. Armed Forces India, 2021, no. 77, pp. 479-482. https://doi.org/10.1016/j.mjafi.2021.05.002.
19. Morrison A.L., Sharpe S., White A.D., Bodman-Smith M. Cheap and commonplace: making the case for BCG and γδ T cells in COVID-19. Front. Immunol., 2021, vol. 12, pp. 743924. Published 2021 https://doi.org/10.3389/fimmu.2021.743924.
20. Mousquer G.T., Peres A., Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis, 2021, no. 126. https://doi.org/10.1016/j.tube.2020.102020.
21. Ręka G., Korzeniowska A., Piecewicz-Szczęsna H. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin (BCG) vaccine on COVID-19 incidence and mortality ‒ review of the literature. Przegl. Epidemiol., vol. 8, no. 2, pp. 290-302. https://doi.org/10.32394/pe.74.22.
22. Ritacco V., Kantor I.N. Tuberculosis and COVID-19: a dangerous relationship. Tuberculosis y COVID-19: Una relación peligrosa. Medicina, no. 80, s. 6, pp. 117-118.
23. Shen H., Chen Z.W. The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection. Cell. Mol. Immunol., 2018, vol. 15, no. 3, pp. 216-225. https://doi.org/10.1038/cmi.2017.128.
24. Stochino C., Villa S., Zucchi P., Parravicini P., Gori A., Raviglione M.C. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur. Respir. J., 2020, vol. 56, no. 1. https://doi.org/10.1183/13993003.01708-2020.
25. Sy K.T.L., Haw N.J.L., Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect. Dis. (Lond.), 2020, vol. 52, no. 12, pp. 902-907. https://doi.org/10.1080/23744235.2020.180635332808838.
26. Tadolini M., Codecasa L.R., García-García J.M., Blanc F.X., Borisov S., Alffenaar J.W., Andréjak C., Bachez P., Bart P. A., Belilovski E., Cardoso-Landivar J., Centis R., D'Ambrosio L., De Souza-Galvão M.L., Dominguez-Castellano A., Dourmane S., Fréchet Jachym M., Froissart A., Giacomet V., Goletti D., Grard S., Gualano G., Izadifar A., Le Du D., Royo M., Mazza-Stalder J., Motta I., Ong CWM, Palmieri F., Rivière F., Rodrigo T., Silva D.R., Sánchez-Montalvá A., Saporiti M., Scarpellini P., Schlemmer F., Spanevello A., Sumarokova E., Tabernero E., Tambyah P.A., Tiberi S., Torre A., Visca D., Zabaleta Murguiondo M., Sotgiu G., Migliori G.B. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur. Respir. J., 2020, vol. 56, no. 1. https://doi.org/10.1183/13993003.01398-2020.
27. Torun S., Ozkaya S., Şen N., Kanat F., Karaman I., Yosunkaya S., Sengoren Dikis O., Asan A., Aydogan Eroglu S., Semih Atal S., Ayten O., Aksel N., Ermiş H., Özçelik N., Demirelli M., Kara I., Sümer S., Marakoğlu K., Üzer F., Uyar Y., Çiçek T., E Ünsal Z., Vatansev H., Botan Yildirim B., Kuruoğlu T., Atilla A., Ersoy Y., Kandemir B., Durduran Y., Goksin Cihan F., Demirbaş N., Yıldırım F., Tatar D., Akcay M.S. The Relationship between COVID-19 Severity and Bacillus Calmette-Guérin (BCG). Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study. Pathog. Glob. Health, 2021, vol. 115, no. 6, pp. 405-411. https://doi.org/10.1080/20477724.2021.1927605.
28. Wang Y., Feng R., Xu J., Hou H., Feng H., Yang H. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J. Med. Virology, 2021, vol. 93, no. 10, pp. 5682-5686. https://doi.org/10.1002/jmv.27119.
29. Yitbarek K., Abraham G., Girma T., Tilahun T., Woldie M. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic. Vaccine, 2020, vol. 38, no. 41, pp. 6374-6380. https://doi.org/10.1016/j.vaccine.2020.08.018.
30. Yongang Z., Binqing F., Xiaohu Zh., Dongsheng W., Changcheng Z., Yingjie Q., Rui S., Zhigang T., Xiaoling X., Haiming W. Aberrant pathogenic GM-CSF+T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv, 2020.
Review
For citations:
Savintseva E.V., Isaeva P.V., Nizamova G.F. Tuberculosis and COVID-19: Medical and Social Aspects. Tuberculosis and Lung Diseases. 2022;100(3):13-17. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-3-13-17
Views:
1291
Email this article 